(secondQuint)A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma.

 Phase 2/3 combination study comparing bortezomib plus one of three doses of tanespimycin in patients with relapsed-refractory multiple myeloma after failure of at least three prior anti-cancer therapy regimens.

 Prior therapy must include bortezomib and lenalidomide.

 Primary objective is to assess the dose-response relationship of objective response rate (ORR) using EBMT/IBMTR criteria of any three dose levels of tanespimycin (KOS-953) in combination with bortezomib after four treatment cycles.

.

 A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma@highlight

This is a phase 2/3, open label trial for patients with relapsed-refractory multiple myeloma.

 Study agent is tanespimycin (KOS-953), at three different dose levels in combination with a fixed dose of bortezomib.

